Research Analysts’ Recent Ratings Updates for Latigo Biotherapeutics (LTGO)

Latigo Biotherapeutics (NASDAQ: LTGO) has recently received a number of price target changes and ratings updates:

• 9/5/2026 – Latigo Biotherapeutics was downgraded by Wall Street Zen from “hold” to “sell”.
• 9/1/2026 – Latigo Biotherapeutics is now covered by Jefferies Financial Group Inc.. They set a “buy” rating and a $50.00 price target on the stock.
• 9/1/2026 – Latigo Biotherapeutics is now covered by Leerink Partners. They set an “outperform” rating and a $36.00 price target on the stock.
• 9/1/2026 – Latigo Biotherapeutics is now covered by Guggenheim. They set a “buy” rating and a $50.00 price target on the stock.
• 9/1/2026 – Latigo Biotherapeutics is now covered by The Goldman Sachs Group, Inc.. They set a “buy” rating and a $73.00 price target on the stock.
• 9/1/2026 – Latigo Biotherapeutics is now covered by Leerink Partners. They set an “outperform” rating and a $36.00 price target on the stock.
• 9/1/2026 – Latigo Biotherapeutics is now covered by Jefferies Financial Group Inc.. They set a “buy” rating and a $50.00 price target on the stock.
• 9/1/2026 – Latigo Biotherapeutics is now covered by Guggenheim. They set a “buy” rating and a $50.00 price target on the stock.
• 9/1/2026 – Latigo Biotherapeutics is now covered by The Goldman Sachs Group, Inc.. They set a “buy” rating and a $73.00 price target on the stock.
• 8/15/2026 – Latigo Biotherapeutics was upgraded by Wall Street Zen to “hold”.

Insiders Place Their Bets

In other news, Director James Tananbaum acquired 140,000 shares of the business’s stock in a transaction that occurred on Monday, August 10th. The shares were bought at an average price of $18.00 per share, with a total value of $2,520,000.00. Following the acquisition, the director directly owned 2,008,024 shares in the company, valued at $36,144,432. The trade was a 7.49% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Also, major shareholder Foresite Capital Management V, acquired 140,000 shares of Latigo Biotherapeutics stock in a transaction that occurred on Monday, August 10th. The shares were purchased at an average price of $18.00 per share, for a total transaction of $2,520,000.00. Following the transaction, the insider directly owned 2,008,024 shares in the company, valued at $36,144,432. The trade was a 7.49% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing.

Latigo Biotherapeutics is a clinical-stage biopharmaceutical company developing non-opioid medicines for the treatment of acute and chronic pain. The company focuses on selectively targeting Nav1.8, a sodium channel involved in the transmission of pain signals, with the goal of developing therapies that may provide pain relief without the risks associated with opioid medications.

Latigo’s pipeline includes small-molecule Nav1.8 inhibitors, led by LTG-001 for acute pain and additional research programs aimed at chronic pain conditions.